ATROVENT SOLUTION

Valsts: Kanāda

Valoda: angļu

Klimata pārmaiņas: Health Canada

Aktīvā sastāvdaļa:

IPRATROPIUM BROMIDE

Pieejams no:

BOEHRINGER INGELHEIM (CANADA) LTD LTEE

ATĶ kods:

R03BB01

SNN (starptautisko nepatentēto nosaukumu):

IPRATROPIUM BROMIDE

Deva:

250MCG

Zāļu forma:

SOLUTION

Kompozīcija:

IPRATROPIUM BROMIDE 250MCG

Ievadīšanas:

INHALATION

Vienības iepakojumā:

20ML

Receptes veids:

Prescription

Ārstniecības joma:

ANTIMUSCARINICS ANTISPASMODICS

Produktu pārskats:

Active ingredient group (AIG) number: 0115643001; AHFS:

Autorizācija statuss:

CANCELLED POST MARKET

Autorizācija datums:

2007-10-11

Produkta apraksts

_ _
_ _
_Page 1 of 33_
PRODUCT MONOGRAPH
Pr
Atrovent
®
(Ipratropium Bromide)
INHALATION SOLUTION
(20 mL bottle, 1 mL and 2 mL Unit Dose Vials)
BRONCHODILATOR
Boehringer Ingelheim (Canada) Ltd.
5180 South Service Road,
Burlington, Ontario
L7L 5H4
Date of Preparation:
September 19, 2003
Date of Revision:
May 16, 2006
Submission Control No:104456
BICL BPI # 0013-05, #0014-06, #0022-05
_ _
_ _
_Page 2 of 33_
Table of Contents
[To update, right-click anywhere in the Table of Contents and select
“Update Field”, “Update
entire table”, click OK.]
PART I: HEALTH PROFESSIONAL
INFORMATION.........................................................3
SUMMARY PRODUCT INFORMATION
........................................................................3
INDICATIONS AND CLINICAL
USE..............................................................................3
CONTRAINDICATIONS
...................................................................................................3
WARNINGS AND
PRECAUTIONS..................................................................................4
ADVERSE
REACTIONS....................................................................................................5
DRUG INTERACTIONS
....................................................................................................9
DOSAGE AND
ADMINISTRATION..............................................................................10
OVERDOSAGE
................................................................................................................10
ACTION AND CLINICAL PHARMACOLOGY
............................................................11
STORAGE AND
STABILITY..........................................................................................13
SPECIAL HANDLING INSTRUCTIONS
.......................................................................14
DOSAGE FORMS, COMPOSITION AND PACKAGING
.............................................14
PART II: SCIENTIFIC INFORMATION
......................................................